Due to the ubiquitous nature of CB1R and CB2R, the ECS is considered a potential target for a wide array of diseases, but CB1R in particular is considered a target for the treatment of pain and neurological disorders such as Parkinson’s disease, Huntington’s disease, and epilepsy (Perez-Olives et al., 2021). This evidence concerns the gene CNR1 and Huntington disease.